沙利度胺联合奥沙利铂和卡培他滨化疗方案治疗转移性结直肠癌临床研究  

Clinical study of thalidomide plus oxaliplatin and capetitabine chemotherapy regimen in the treatment of metastatic colorectal cancer

作　　者：魏振[1,2,3] 章志翔[1] 

机构地区：[1]天津医科大学总医院普外科,天津300052 [2]天津医科大学静海临床学院 [3]静海县医院外二科,天津301600

出　　处：《中国临床药理学杂志》2014年第10期904-906,共3页The Chinese Journal of Clinical Pharmacology

摘　　要：目的评价沙利度胺联合奥沙利铂(L-OHP)与卡培他滨(CAP)(XELOX)化疗方案与单纯XELOX方案治疗晚期转移性结直肠癌(amCRC)的疗效及安全性。方法 103例晚期转移性结直肠癌患者分为沙利度胺联合XELOX方案化疗(试验组)46例和单纯用XELOX方案化疗(对照组)57例。对照组:静脉滴注L-OHP 130 mg·m-2,持续4 h;口服CAP 1000 mg·m-2,bid,l^14 d;试验组:在对照组基础上口服沙利度胺200 mg,qn,1~14 d;21 d为1周期,化疗3周期后进行疗效评价。结果试验组客观有效率(ORR)为34.8%,显著高于对照组的14.0%(P<0.05);试验组中位疾病进展时间为8.1个月,显著高于对照组6.2个月(P<0.05);2组患者胃肠道反应及血液学毒性差别无统计学意义(P>0.05)。结论沙利度胺联合XELOX化疗方案可提高晚期转移性结直肠癌的临床疗效,延长患者无病生存时间,且不增加患者不良反应。Objective To evaluate clinical efficacy and safety of thalido-mide plus oxaliplatin （ L -OHP） and capecitabine （ CAP） regimen （XELOX） and single XELOX chemotherapy regimen in the treatment of advanced metastatic colorectal cancer （ amCRC ） . Methods One hundred and three subjects with amCRC were recruited and randomly divided into the XELOX （control group, n =57） and XELOX plus tha-lidomide（treatment group, n =46） group.Control group： L -OHP 130 mg·m^-2 through intravenous infusion, lasting for 4 h, CAP 1000 mg· m^-2 , bid, po, l to 14 days. Treatment group： L - OHP 130 mg· m^-2 through intravenous infusion , lasting for 4 h, CAP 1000 mg· m^-2 , bid, po, l to 14 days, as well as thalidomide 200 mg, qn, po, 1 to 14 days.21 days as a cycle.Results The objective response rate （ORR） in treatment group was 34.8%, significantly higher than that of control group （14.0%） （P 〈0.05）; the median time to progression in the treatment group was 8.1 months, much longer than that in the control group （6.2 months） （P 〈0.05）.No statistical differences of gastrointesti -nal reactions and hematologic toxicity were found between the two groups （P 〉0.05 ） .Conclusion Thalidomide plus XELOX chemotherapy regimen can significantly increase the clinical efficacy on patients with amCRC without increasing adverse reactions .

关 键 词：晚期结直肠癌 奥沙利铂 卡培他滨 沙利度胺 

分 类 号：R735.37[医药卫生—肿瘤] R979.5[医药卫生—临床医学]